Treatment Adherence with Early Prescription of Long-Acting Injectable Antipsychotics in Recent-Onset Schizophrenia
Authors:
Open Access
- 3 April 2012
- journal article
- research article
- Published by Hindawi Limited in Schizophrenia Research and Treatment
- Vol. 2012, 1-5
Abstract
Although response to treatment for the first episode of schizophrenia is generally favourable, nonadherence with the treatment is the first cause of relapse and rehospitalisation within the next few years. Long-acting injectable antipsychotics (LAIAs) combine the advantages of the newer antipsychotics and the long-acting formulation. The evaluation concerns 25 schizophrenic patients hospitalised for the first time, treated with risperidone long-acting injectable (RLAI) associated with reintegration methods, and followed up for at least 18 months. Clinical observation was completed using Clinical Global Impression (CGI) scale and Global Assessment of Functioning (GAF). Clinical improvement was coupled with a good reintegration rate, very few relapse, or rehospitalisation. Bimonthly injection combined with psychosocial methods improved interactive followup, and therefore patients’ compliance with the treatment. Treating with LAIA as early as possible, from the first episode if possible, can reduce relapse, number and duration of rehospitalisation, and cognitive symptoms and improve the quality of life and prognosis.Keywords
This publication has 44 references indexed in Scilit:
- Psychiatrists’ attitude to antipsychotic depot treatment in patients with first-episode schizophreniaEuropean Psychiatry, 2011
- Risperidone Nonadherence and Return of Positive Symptoms in the Early Course of SchizophreniaAmerican Journal of Psychiatry, 2011
- The cost of relapse and the predictors of relapse in the treatment of schizophreniaBMC Psychiatry, 2010
- A Randomized Controlled Trial of Long-Acting Injectable Risperidone vs Continuation on Oral Atypical Antipsychotics for First-Episode Schizophrenia PatientsThe Journal of Clinical Psychiatry, 2009
- Is Early Intervention in Psychosis Cost-Effective Over the Long Term?Schizophrenia Bulletin, 2009
- Oral versus injectable antipsychotic treatment in early psychosis: Post hoc comparison of two studiesClinical Therapeutics, 2008
- Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injectionInternational Clinical Psychopharmacology, 2008
- Long-Acting Injectable Risperidone in the Treatment of Subjects With Recent-Onset PsychosisJournal of Clinical Psychopharmacology, 2008
- The case for long‐acting antipsychotic agents in the post‐CATIE eraActa Psychiatrica Scandinavica, 2007
- Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectableJournal of Psychopharmacology, 2005